Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Aug 16, 2023 (filed on Aug 17, 2023)Insider Name:Ajer Jeffrey RobertOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,000Price:$90.00
-
Aug 10, 2023 (filed on Aug 11, 2023)Insider Name:Fuchs Henry JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,000Price:$90.43
-
Aug 09, 2023 (filed on Aug 10, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,360Price:$93.30
-
Aug 08, 2023 (filed on Aug 09, 2023)Insider Name:Davis George EricOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-11,000Price:$89.42
-
Aug 08, 2023 (filed on Aug 09, 2023)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,000Price:$88.29
-
Aug 07, 2023 (filed on Aug 09, 2023)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,000Price:$88.10
-
Jun 29, 2023 (filed on Jun 30, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-576Price:$88.93
-
Jun 29, 2023 (filed on Jun 30, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,602Price:$88.93
-
Jun 29, 2023 (filed on Jun 30, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,602Price:$88.93
-
May 23, 2023 (filed on May 24, 2023)Insider Name:Slamon DennisOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:4,190Price:--
Filings by filing date
-
Aug 16, 2023 (filed on Aug 17, 2023)Insider Name:Ajer Jeffrey RobertOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,000Price:$90.00
-
Apr 28, 2023 (filed on Aug 17, 2023)Insider Name:Ajer Jeffrey RobertOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:318Price:$66.88
-
Aug 10, 2023 (filed on Aug 11, 2023)Insider Name:Fuchs Henry JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-12,000Price:$90.43
-
Aug 09, 2023 (filed on Aug 10, 2023)Insider Name:Guyer Charles GregOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-5,360Price:$93.30
-
Aug 08, 2023 (filed on Aug 09, 2023)Insider Name:Davis George EricOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-11,000Price:$89.42
-
Aug 08, 2023 (filed on Aug 09, 2023)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-6,000Price:$88.29
-
Aug 07, 2023 (filed on Aug 09, 2023)Insider Name:Bienaime Jean JacquesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-4,000Price:$88.10
-
Jun 29, 2023 (filed on Jun 30, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-576Price:$88.93
-
Jun 29, 2023 (filed on Jun 30, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,602Price:$88.93
-
Jun 29, 2023 (filed on Jun 30, 2023)Insider Name:Mueller BrianOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-4,602Price:$88.93
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 105 Digital Dr NOVATO CA 94949-8703 |
Tel: | N/A |
Website: | https://www.biomarin.com |
IR: | See website |
Key People | ||
Jean-Jacques Bienaime Chairman of the Board, Chief Executive Officer | Brian R. Mueller Chief Financial Officer, Executive Vice President - Finance | Henry J. Fuchs President - Worldwide Research and Development |
C. Greg Guyer Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer | G. Eric Davis Executive Vice President, Secretary, Chief Legal Officer | Jeff Robert Ajer Executive Vice President, Chief Commercial Officer | Erin Burkhart Group Vice President, Chief Accounting Officer |
Business Overview |
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies that address the root cause of genetic conditions. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Roctavian (valoctocogene roxaparvovec) and Voxzogo (vosoritide). The Roctavian is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. The Company's clinical development programs include BMN 331, an AAV5 mediated gene therapy for people living with Hereditary Angioedema (HAE) and BMN 255 is a small-molecule therapy that is designed to treat hyperoxaluria in chronic liver disease. |
Financial Overview |
For the six months ended 30 June 2023, Biomarin Pharmaceutical Inc revenues increased 13% to $1.19B. Net income decreased 28% to $106.9M. Revenues reflect Voxzogo segment increase from $54M to $201.2M, Palynziq1 segment increase of 18% to $137.2M, Middle East segment increase of 79% to $117.3M, United States segment increase of 12% to $358.4M. Net income was offset by Gain on sale of nonfinancial assets decrease from $108M (income) to $0K. |
Employees: | 3,082 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $16,628M as of Jun 30, 2023 |
Annual revenue (TTM): | $2,235M as of Jun 30, 2023 |
EBITDA (TTM): | $192.50M as of Jun 30, 2023 |
Net annual income (TTM): | $99.99M as of Jun 30, 2023 |
Free cash flow (TTM): | $40.91M as of Jun 30, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 188,174,773 as of Jul 28, 2023 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |